Welcome to our dedicated page for Inspira Technologies Oxy Bhn SEC filings (Ticker: IINN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer. Inspira files Form 6-K current reports under the Securities Exchange Act of 1934, along with registration statements on Form F-3 and Form S-8 referenced in those reports. These filings document key events in the company’s development as a commercial-stage medical device and diagnostics business focused on respiratory support and blood monitoring.
Recent Form 6-K reports describe transactions such as a registered direct offering of ordinary shares and a Standby Equity Purchase Agreement that together outline Inspira’s equity financing tools. Other 6-Ks incorporate press releases on clinical and regulatory milestones, including progress with the HYLA non-invasive blood sensor, regulatory steps for the INSPIRA ART100 system in the United Arab Emirates, and financial results and business updates. Filings also cover shareholder meeting materials, board and executive changes, and adjustments to sales agreements for ordinary shares.
Through this page, users can review Inspira’s SEC-reported information on capital structure, financing arrangements, and material operational updates. Stock Titan’s tools can surface new 6-K submissions in real time and help summarize their contents, allowing readers to quickly understand how each filing relates to topics such as product commercialization, clinical studies, or corporate governance. For deeper analysis, investors can examine attachments referenced in the 6-Ks, including financial statements, management’s discussion and analysis, and opinions related to securities offerings.
Inspira Technologies Oxy B.H.N. Ltd. submitted a report describing the termination of two equity financing arrangements: its sales agreement with A.G.P./Alliance Global Partners and its Standby Equity Purchase Agreement with YA II PN, Ltd. The company states that no obligations remain and no further advances will be made under either facility. Management explains that ending these facilities aligns with its goal of maintaining a disciplined capital structure as it prepares for its next strategic phase.
The report also highlights that Inspira is a commercial-stage medical device company focused on advanced respiratory support and blood monitoring, including its FDA-cleared INSPIRA ART100 system for cardiopulmonary bypass in the U.S., ECMO-related uses outside the U.S., and development of the INSPIRA ART500 and HYLA blood sensor platform.
Inspira Technologies reported its full-year 2025 results, showing initial commercialization with revenues of about $289,000 from the INSPIRA ART100 system and a net loss of $13.22 million. Operating expenses rose to $13.62 million, driven mainly by higher research and development and general and administrative costs.
Cash, cash equivalents and deposits totaled $3.16 million as of December 31, 2025, with a subsequent registered direct offering adding approximately $4.75 million in gross proceeds. The company also raised about $4.25 million in a separate securities sale and reclassified certain warrants as equity, and believes it now meets Nasdaq’s $2.5 million shareholders’ equity requirement. Inspira terminated its proposed acquisition of Bio-View Ltd.’s liquid biopsy business and is evaluating other strategic alternatives while continuing clinical and early commercial deployment of the ART100 and development of HYLA.
Inspira Technologies Oxy B.H.N. Ltd. files its annual Form 20-F, outlining its respiratory-focused medical device business and key risks. The company develops the INSPIRA ART blood-oxygenation platform, FDA-cleared INSPIRA ART100 cardiopulmonary bypass system, and HYLA real-time blood sensor targeting ICU and surgical settings.
The report highlights intense competition from large global medtech companies, dependence on distributors, supply-chain and cybersecurity risks, and heavy regulatory oversight in the U.S., EU and other markets. Inspira reports an accumulated deficit of about $80 million as of December 31, 2025, ongoing operating losses, limited cash resources, and substantial doubt about its ability to continue as a going concern.
The company notes it had approximately $3.1 million in cash, cash equivalents and deposits and working capital of about $1.6 million at December 31, 2025, which it expects will fund operations for roughly six months. Inspira also discloses Nasdaq minimum-bid-price deficiencies in March 2025 and February 2026, regaining compliance once but again facing a deadline of August 10, 2026 to restore its share price to at least $1.00 to avoid potential delisting.
Inspira Technologies Oxy B.H.N. Ltd. has established a wholly owned subsidiary as part of a revised corporate structure. The company plans to transfer its existing medical business activities into this new entity, concentrating its operating business under the subsidiary.
The report is also incorporated by reference into Inspira Technologies’ existing Form F-3 and Form S-8 registration statements, so that these U.S. securities filings reflect the updated corporate structure from the date of this report.
Inspira Technologies OXY B.H.N. Ltd executive Shabtay Abraham, the COO and VP of R&D, filed an initial ownership report showing his equity position in the company. He directly holds 1,332,713 ordinary shares, plus employee share options over 57,144 and 38,095 ordinary shares at an exercise price of $0.12 per share, expiring on April 20, 2030. His holdings also include multiple restricted stock unit grants that vest quarterly through early 2028 and additional RSUs that vest upon milestone achievements, reflecting a compensation package strongly tied to the company’s long-term performance.
Inspira Technologies OXY B.H.N. Ltd reported the initial holdings of its Chief Financial Officer, Tehila Yafit. She directly holds 946,395 ordinary shares, which include multiple restricted stock unit (RSU) grants that vest through February 1, 2028 and upon certain milestones.
She also holds employee share options over 13,605 ordinary shares with an exercise price of $0.12 per share. These options were granted on February 21, 2021, became fully vested as of February 23, 2024, and expire on February 21, 2031.
Inspira Technologies OXY B.H.N. Ltd director Tal Parnes filed an initial ownership report showing equity holdings in the company. Parnes directly holds 210,000 ordinary shares, plus share options covering 4,701 ordinary shares at an exercise price of $0.1200 per share, with expiration on April 20, 2030. The position also includes 10,001 restricted stock units vesting quarterly until February 1, 2027 and 100,001 restricted stock units vesting quarterly until February 1, 2028, indicating a mix of current ownership and future potential shares through options and RSUs.
Inspira Technologies OXY B.H.N. Ltd director Matza Sivan filed an initial ownership report showing beneficial ownership of 30,000 ordinary shares. These include 9,999 restricted stock units that vest on October 21, 2026 and 20,001 restricted stock units that vest quarterly from January 21, 2027 until October 21, 2028.
Inspira Technologies OXY B.H.N. Ltd director Amit Lior filed an initial ownership report showing beneficial ownership of 61,667 ordinary shares. This includes 10,001 restricted stock units vesting quarterly until February 1, 2027 and 20,001 restricted stock units vesting quarterly until February 1, 2028, all held directly.
Inspira Technologies OXY B.H.N. Ltd Chief Technology Officer Daniella Yechezkely Hayon reported beneficial ownership of 830,000 ordinary shares as of the reported date. This is an initial ownership filing rather than a new trade.
The position includes restricted stock units: 36,667 RSUs vesting quarterly until February 1, 2027, 100,001 RSUs vesting quarterly until February 1, 2028, 100,000 RSUs vesting on July 1, 2026, 200,000 RSUs vesting quarterly beginning October 1, 2026 until July 1, 2028, and 100,000 RSUs that vest upon achieving specified milestones.